Abstract. Consecutive expression of the high-risk human papillomavirus (HPV) oncoproteins, E6 and E7, is pivotal for malignant transformation and maintenance of the malignant phenotype. These oncogenes may be potential targets of gene silencing-based molecular therapies for human cervical cancer. The aim of the present study was to evaluate the efficacy of chitosan-based HPV16 E7 siRNA delivery and the chitosan/HPV16 E7 siRNA complex in the induction of apoptosis in CaSki cells constitutively expressing HPV16 E6 and E7. Chitosan/siRNA nanoparticles were prepared by adding a chitosan solution drop-wise to an equal volume of siRNA solution. Formation of the chitosan/siRNA complex was verified by gel retardation assays and the entry of siRNA into the cells was confirmed by fluorescence microscopy. Expression of HPV16 E7 was examined by western blot analysis and apoptotic cells were detected by TUNEL staining. Chitosan formed complexes with HPV16 E7 siRNA. The chitosan/siRNA nanoparticles were efficiently delivered into CaSki cells and were observed to induce apoptosis. In conclusion, chitosan is suitable for use as a carrier for delivery of siRNA into cancer cells. The delivery of chitosan/HPV16 E7 siRNA nanoparticles in vivo may serve as a promising therapy for cervical cancer.
Introduction
Cervical cancer is a malignant tumor and the second most malignant cancer in females. It is a major threat to female health worldwide. Globally, 500,000 new cases and >250,000 mortalities occur each year. These figures account for ~5% of all cancer cases worldwide with ~80% of new cases reported in developing countries (1) . In China, the annual incidence of new cervical cancer cases exceeds 130,000, accounting for 28.8% of new cases worldwide (2) . An estimated 20,000 individuals succumb to cervical cancer every year in China, and incidence is increasing in young adults (3) .
The most important risk factor for cervical cancer is infection with human papilloma virus (HPV), which accounts for 50-70% of all cervical cancer cases worldwide. Oncoproteins encoded by two early HPV genes, E6 and E7, are important for cell cycle control. E6 and E7 are required for malignant transformation and maintenance of malignant phenotypes and are crucial for the development and progression of cervical cancer (4) (5) (6) (7) (8) . HPV16 E7 binds to key tumor suppressors and inhibits their activity. One of the most important targets of HPV16 E7 is the retinoblastoma protein (pRb) family which contains pRb, p107 and p130. In normal cells, pRb proteins are major regulators of the cell cycle, binding directly to the E2F transcription factor and negatively regulating its activity, thus inhibiting expression of E2F target genes important for cell cycle progression (9) (10) (11) (12) (13) (14) (15) (16) . In HPV16 E7-overexpressing cells, HPV16 E7 binds to pRb via its CR3 region. This binding induces pRb degradation through the ubiquitin-proteasome system and releases E2F into the cytosol (17) (18) (19) (20) . The free E2F translocates to the nucleus, activates the transcription of its target genes and promotes cell transformation. Therefore, suppression of HPV16 E7 expression is likely to inhibit cell growth and induce apoptosis and senescence, which may limit the growth of cancer cells.
RNA interference (RNAi) has become widely used as an experimental tool to analyze gene function and holds great promise in the field of gene therapy in cancer. However, several limitations restrict its use in basic research and clinical application. First, siRNA is not stable and is easily degradated by enzymes. Second, the delivery of siRNA into cells is a great challenge. Although liposome and cationic polymers have been used as carriers for siRNA delivery, these reagents are toxic to cells and not suitable for in vivo transfection. Chitosan is derived from chitin, the most abundant biopolymer in nature following cellulose and is a biologically safe, non-toxic, biodegradable and biocompatible polymer. It contains abundant -NH2 groups and is therefore positively charged at specific pH levels, enabling it to complex with negatively charged nanoparticles (21, 22 Preparation and characterization of chitosan/siRNA nano particles. Chitosan was dissolved in aqueous acetic acid (0.1 M sodium acetate/0.1 M acetic acid, pH 4.5) to prepare various concentrations of chitosan solution (25-300 µg/ml). Chitosan/siRNA nanoparticles were prepared by adding a chitosan solution drop-wise to an equal volume of siRNA solution (20 µg/ml) and incubating at room temperature for 30 min.
The chitosan was complexed with siRNA at a weight ratio of 1.25:1-15:1. The size and ζ potential of nanoparticles were measured using the submicron particle analysis system 4700 (Beckman Coulter Inc., Miami, FL, USA) and the Zetasizer Nano S (Malvern Instruments, Malvern, UK), respectively.
Measurement of siRNA loading efficiency. Chitosan and siRNA were mixed and the mixture was centrifuged and the absorbance of supernatant was measured at 260 nm to determine the concentration of free siRNA. The loading efficiency of siRNA was calculated by comparing the amount of siRNA that was not present in the supernatant to the amount of total siRNA.
Gel retardation assay. The binding of siRNA to chitosan was determined by electrophoresis using a 4% agarose gel (low melting point). Nanoparticles with various chitosan/siRNA weight ratios were loaded onto the gel and subjected to electrophoresis. siRNA was visualized by ultraviolet light.
Serum stability assay. Chitosan/siRNA nanoparticles (~5 µg siRNA, 200 µl) were incubated with an equal volume of 20% fetal bovine serum (FBS) in Dulbecco's modified Eagle's medium (DMEM) at 37˚C. At various time points (0, 0.5, 2, 4, 7, 24, 48 and 72 h), 30 µl mixture was saved and stored at -20˚C.
Characterization of the biological activity of chitosan/siRNA nanoparticles. CaSki cells were seeded in 96-well plates at a density of 3x10 4 cells/well and cultured in DMEM containing 10% FBS (no antibiotics) for 24 h prior to transfection. Chitosan/siRNA particles were added directly into the culture medium and the cells were cultured for an additional 24-48 h prior to examination by fluorescence microscopy.
Cell toxicity assay. Toxicity of chitosan was determined by the cell viability of chitosan/siRNA nanoparticles, as described previously (23).
TUNEL staining. CaSki cells were seeded in 96-well plates at a density of 3x10 4 cells/well and cultured in DMEM containing 10% FBS (no antibiotics) for 24 h prior to transfection. Chitosan/siRNA particles were added directly to the culture medium and the cells were cultured for an additional 24-48 h. Cell death was detected using an in situ Cell Death Detection kit (Nanjing KeyGen Biotech, Co., Ltd., Nanjing, China).
Western blot analysis. CaSki cells were seeded in 6-well plates at a density of 4x10 4 cells/well. Following plating (24 h), cells were fed with fresh complete media and the chitosan/siRNA nanoparticles were added to the media. Following an additional 48 h, cells were harvested with RIPA buffer. Samples were subjected to SDS-PAGE and immunoblotted with antibodies against HPV16 E7 and β-actin (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Statistical analysis. Data were analyzed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA) and expressed as mean ± SE. P<0.05 was considered to indicate a statistically significant difference.
Results
Size of chitosan/siRNA nanoparticles. The chitosan/siRNA particles formed by simple complexation had a diameter between 185 and 465 nm and the size increased with the increasing weight ratio of chitosan to siRNA (Fig. 1) . Table I , the surface charge of chitosan/siRNA particles increased with increasing chitosan concentration (the amount of siRNA remained constant). Increased chitosan concentration increased the positive charge of the particles, preventing aggregation of the particles and enhancing their interaction with negatively charged cell membranes.
Surface charge. As revealed in
Interaction of siRNA with chitosan. Since chitosan and siRNA carry opposite charges, they are attracted to one another in solutions with specific pH values. Complete attachment of siRNA to chitosan was observed when chitosan and siRNA were mixed at a weight ratio of 100:1 (Fig. 2) . The loading efficiency of siRNA was 72±1.5%.
Stability of siRNA in serum. Naked siRNA was not stable in serum and was susceptible to enzyme digestion. When complexed with chitosan, the rate of degradation was markedly reduced (Fig. 3) , indicating that chitosan protects siRNA from nuclease attack.
Biological activity of chitosan/siRNA nanoparticles. To examine the transfection efficiency of chitosan/siRNA nanoparticles, chitosan was complexed with fluorescence-labeled HPV16 E7 siRNA and their accumulation in CaSki cells was monitored. As demonstrated in Fig. 4 , chitosan/siRNA particles 
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were efficiently tranfected into cells following 24-h incubation. Protein levels of HPV16 E7 in CaSki cells were analyzed by western blot analysis and identified to be significantly downregulated ( Fig. 5; P<0 .05), indicating that chitosan/HPV16 E7 nanoparticles suppress expression of HPV16 E7.
Induction of apoptosis in CaSki cells by chitosan/HPV16 E7 nanoparticles.
To examine the effect of chitosan/HPV16 E7 nanoparticles on cell apoptosis, apoptotic cells were detected using the TUNEL assay in cells treated with chitosan/HPV16 E7 nanoparticles. A significantly higher number of apoptotic cells were detected in cells treated with chitosan/HPV16 E7 nanoparticles compared with cells treated with chitosan/mock siRNA particles ( Fig. 6 ; P<0.05).
Discussion
In the present study, chitosan/siRNA nanoparticles were prepared by simple complexation (24) . The size and shape of nanoparticles is critical for efficient transfection of mammalian cells and distribution of nanoparticles in living cells (25) . Previous studies have reported that nanoparticles exhibit higher levels of intracellular uptake compared with microparticles (26) (27) (28) . This property is crucial for gene transfer, since the uptake of chitosan/DNA nanoparticles and their release from lysosomes are rate-limiting steps in this process (29, 30) . Similar to DNA and oligodeoxyribonucleotides, siRNA is also taken up by cells (31) . However, RNAi is not induced if siRNA fails to reach the cytoplasm (31) . Using a carrier aids siRNA transfer into the intracellular compartment and protects it from enzyme degradation in lysosomes, thus efficiently inducing RNAi. In the present study, chitosan/siRNA nanoparticles were prepared with a size <500 nm in diameter which were easily taken up by cells. The diameter of the nanoparticles increases with the increasing weight ratio of chitosan to siRNA. Therefore, nanoparticles of suitable sizes were prepared by adjusting the weight ratio of chitosan to siRNA. Binding of siRNA to chitosan was demonstrated by gel retardation assay. The retarded migration of siRNA in agarose gel revealed binding of siRNA to chitosan. However, this binding is not as tight as that of DNA to chitosan, since DNA, but not siRNA, is concentrated by low concentration chitosan (25 µg/ml), indicating that siRNA binds to chitosan in a different manner to that of DNA to chitosan. Previously, the size of chitosan/DNA nanoparticles following concentration was reported to be 1,000 times smaller than that without concentration (32, 33) and the minimal size of DNA for concentration was 800 bp (32, (34) (35) (36) . In contrast to DNA, linearized siRNA is much shorter (21 bp). This property may account for the weak interaction of siRNA with chitosan. Since the size of nanoparticles remains unchanged following complexation, multiple, but not single siRNA may complex with chitosan.
The major cause of cervical cancer is infection with high-risk HPV. The integration of viral DNA into human genomes leads to the constitutive expression of oncoproteins E6 and E7, altering the cell cycle, immortalizing cells and causing cancer. Therefore, suppression of E7 expression may reverse the transformation process and induce apoptosis or senescence. Chitosan/HPV16 E7 siRNA nanoparticles were efficiently transfected into the cells (Fig. 4) and were found to suppress HPV16 E7 expression (Fig. 5) . In addition, TUNEL staining revealed that apoptosis was induced in the CaSki cells. These results are consistent with previous studies. Chang et al (37) demonstrated that siRNA-mediated suppression of HPV E6 and E7 inhibited the growth of tumor cells from cervical cancer. Sima et al (38) reported that HPV16 E7 shRNA inhibits E6 and E7 expression and induces apoptosis in cancer cells via activation of p53, p21 and Rb. More recently, Guo et al (23) screened a phage display peptide library, identifying a heptapeptide which promotes degradation of E7 and prevent formation of E7/pRb complexes. This peptide induced G 1 phase arrest by restoration of pRb activity, reinstating its ability to inhibit E2F activity. In addition, downregulation of E7 was reported to increase levels of p53 and induce apoptosis. Results of the current and previous studies indicate that suppression of HPV16 E7 by chitosan/siRNA nanoparticles inhibits growth of tumor cells and induces their apoptosis, which may serve as a potential therapy for cervical cancer. 
